The prognostic value of cyclin D1 expression in the survival of cancer patients: a meta-analysis

Moradi Binabaj, Maryam, Bahram, Afsane, Khazaei, Majid, Ryzhikov, Mikhail, Ferns, Gordon A and Hassanian, Seyed Mahdi (2019) The prognostic value of cyclin D1 expression in the survival of cancer patients: a meta-analysis. Gene, 728. a144283. ISSN 0378-1119

[img] Image (TIFF) - Supplemental Material
Restricted to SRO admin only until 13 December 2020.
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (39kB)
[img] Image (TIFF) - Supplemental Material
Restricted to SRO admin only until 13 December 2020.
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (288kB)
[img] Image (TIFF) - Supplemental Material
Restricted to SRO admin only until 13 December 2020.
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (393kB)
[img] Image (TIFF) - Supplemental Material
Restricted to SRO admin only until 13 December 2020.
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (22kB)
[img] PDF - Accepted Version
Restricted to SRO admin only until 13 December 2020.
Available under License Creative Commons Attribution-NonCommercial No Derivatives.

Download (467kB)

Abstract

Background
The relationship between the expression of cyclin D1 and cancer prognosis and outcomes in different malignancies has not been fully elucidated.

Aims
In the presented meta-analysis, we assessed the association between the expression level of cyclin D1 with overall survival (OS) in several cancers.

Methods
Eligible studies were identified using PubMed, EMBase, Scopus, Web of Sciences and Cochrane Library databases. For the prognostic meta-analysis, study-specific hazard ratios (HRs) of tissue cyclin D1 for survival were obtained. Finally we pooled data derived from one hundred and eight studies comprising 19,224 patients with 10 different cancer types.

Results
In the pooled analysis, high expression of cyclin D1 was significantly related to a poor OS with a pooled HR of 1.11 (95% CI: 1.02–1.20, P = 0.015; random-effects). Sub-group analysis revealed that high expression of cyclin D1 was related to worse OS of head and neck cancers (HR = 2.08, 95% CI: 1.75–2.47; P < 0.001), but not in breast (HR = 1.033, 95% CI: 0.873–1.223, P = 0.702), gastrointestinal (HR = 1.025, 95% CI:0.824–1.275; P = 0.825), bladder (HR = 0.937, CI: 0.844–1.041; P = 0.225) and in lung cancer patients (HR = 1.092, CI: 0.819–1.455; P = 0.549).

Conclusion
Further large, prospective, and well-designed trials are warranted to elucidate the precise clinical importance of cyclin D1 overexpression in the prognosis of cancer patients receiving different treatment regimens.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Subjects: R Medicine > R Medicine (General)
Depositing User: Cherie Elody
Date Deposited: 06 Jan 2020 09:51
Last Modified: 06 Jan 2020 10:00
URI: http://sro.sussex.ac.uk/id/eprint/89140

View download statistics for this item

📧 Request an update